PDF Publication Title:
Text from PDF Page: 013
compounds induce CS in ABC-transporter-expressing drug- resistant cells. The novel aspect of the CS phenomenon reported here is that two compounds, which are individually neither toxic to the resistant nor to the parental cells, can evoke CS in resistant cells when they act synergistically. The work presented here therefore reveals a mechanism of CS that can be targeted rationally because it uses a known phenotypic differ- ence (i.e. inducible ATP depletion by overexpressed MDR transporters) to kill resistant cells. Acknowledgments—We thank Dr. Susan Bates (NCI) for the generous gift of the ABCG2-expressing cell lines. We also thank Dr. Suneet Shukla, and Joseph Koos for guidance in membrane preparation and ATPase assays and Gowthamy Venkidasubramonian for assistance in maintaining cell lines. Finally, we thank Dr. Gary Luker for excel- lent suggestions and a clinical perspective of the relevance of MDR efflux pumps. REFERENCES 1. Szakács, G., Hall, M. D., Gottesman, M. M., Boumendjel, A., Kachadou- rian, R., Day, B. J., Baubichon-Cortay, H., and Di Pietro, A. (2014) Target- ing the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem. Rev. 114, 5753–5774 2. Hardwick, L. J., Velamakanni, S., and van Veen, H. W. (2007) The emerg- ing pharmacotherapeutic significance of the breast cancer resistance pro- tein (ABCG2). Br. J. Pharmacol. 151, 163–174 3. Krishnamurthy, P., and Schuetz, J. D. (2006) Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46, 381– 410 4. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95, 15665–15670 5. Doyle, L., and Ross, D. D. (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340 –7358 6. Kusuhara, H., Furuie, H., Inano, A., Sunagawa, A., Yamada, S., Wu, C., Fukizawa, S., Morimoto, N., Ieiri, I., Morishita, M., Sumita, K., Mayahara, H., Fujita, T., Maeda, K., and Sugiyama, Y. (2012) Pharmacokinetic inter- action study of sulphasalazine in healthy subjects and the impact of cur- cumin as an in vivo inhibitor of BCRP. Br. J. Pharmacol. 166, 1793–1803 7. Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug re- sistance. Nat. Rev. Cancer 5, 275–284 8. Ding, X. W., Wu, J. H., and Jiang, C. P. (2010) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 86, 631– 637 9. Haimeur, A., Conseil, G., Deeley, R. G., and Cole, S. P. (2004) The MRP- related and BCRP/ABCG2 multidrug resistance proteins: biology, sub- strate specificity and regulation. Curr. Drug Metab. 5, 21–53 10. Shukla, S., Wu, C. P., and Ambudkar, S. V. (2008) Development of inhib- itors of ATP-binding cassette drug transporters: present status and chal- lenges. Expert. Opin. Drug. Metab. Toxicol. 4, 205–223 11. Leonard, G. D., Polgar, O., and Bates, S. E. (2002) ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs 3, 1652–1659 12. Silva, A. S., Kam, Y., Khin, Z. P., Minton, S. E., Gillies, R. J., and Gatenby, R. A. (2012) Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 72, 6362– 6370 13. Moreno-Sánchez, R., Rodríguez-Enríquez, S., Saavedra, E., Marín- Hernández, A., and Gallardo-Pérez, J. C. (2009) The bioenergetics of can- cer: is glycolysis the main ATP supplier in all tumor cells? BioFactors 35, 209 –225 14. Shim, H., Chun, Y. S., Lewis, B. C., and Dang, C. V. (1998) A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl. Acad. Sci. U.S.A. 95, 1511–1516 15. Leist, M., Single, B., Castoldi, A. F., Kühnle, S., and Nicotera, P. (1997) Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185, 1481–1486 16. Fearon,K.C.,Plumb,J.A.,Burns,H.J.,andCalman,K.C.(1987)Reduc- tion of the growth rate of the Walker 256 tumor in rats by rhodamine 6G together with hypoglycemia. Cancer Res. 47, 3684 –3687 17. Gottesman,M.M.,Fojo,T.,andBates,S.E.(2002)Multidrugresistancein cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48 –58 18. Pluchino,K.M.,Hall,M.D.,Goldsborough,A.S.,Callaghan,R.,andGot- tesman, M. M. (2012) Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98 –105 19. Szakács, G., Annereau, J. P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., Weinstein, J. N., and Gottesman, M. M. (2004) Predicting drug sensitivity and resis- tance: profiling ABC transporter genes in cancer cells. Cancer Cell 6, 129 –137 20. Gatenby,R.A.,Silva,A.S.,Gillies,R.J.,andFrieden,B.R.(2009)Adaptive therapy. Cancer Res. 69, 4894 – 4903 21. Laberge,R.M.,Karwatsky,J.,Lincoln,M.C.,Leimanis,M.L.,andGeorges, E. (2007) Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochem. Pharmacol. 73, 1727–1737 22. van der Heijden, J., de Jong, M. C., Dijkmans, B. A., Lems, W. F., Oerle- mans, R., Kathmann, I., Scheffer, G. L., Scheper, R. J., Assaraf, Y. G., and Jansen, G. (2004) Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann. Rheum. Dis. 63, 131–137 23. Heffeter, P., Jakupec, M. A., Körner, W., Chiba, P., Pirker, C., Dornet- shuber, R., Elbling, L., Sutterlüty, H., Micksche, M., Keppler, B. K., and Berger, W. (2007) Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem. Pharmacol. 73, 1873–1886 24. Karwatsky, J., Lincoln, M. C., and Georges, E. (2003) A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensi- tivity. Biochemistry 42, 12163–12173 25. Shishodia, S., Chaturvedi, M. M., and Aggarwal, B. B. (2007) Role of cur- cumin in cancer therapy. Curr. Probl. Cancer 31, 243–305 26. Chearwae, W., Shukla, S., Limtrakul, P., and Ambudkar, S. V. (2006) Mod- ulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcu- min. Mol. Cancer Ther. 5, 1995–2006 27. Hladky, S. B., and Haydon, D. A. (1970) Discreteness of conductance change in bimolecular lipid membranes in the presence of certain antibi- otics. Nature 225, 451– 453 28. Noble, D. (1980) Mechanism of action of therapeutic levels of cardiac glycosides. Cardiovasc. Res. 14, 495–514 29. Schatzmann, H. J. (1953) Cardiac glycosides as inhibitors of active potas- sium and sodium transport by erythrocyte membrane. Helv. Physiol. Phar- macol. Acta 11, 346 –354 30. Nobes, C. D., Lakin-Thomas, P. L., and Brand, M. D. (1989) The contri- bution of ATP turnover by the Na/K-ATPase to the rate of respiration of hepatocytes: effects of thyroid status and fatty acids. Biochim. Biophys. Acta 976, 241–245 31. James, A. M., Sheard, P. W., Wei, Y. H., and Murphy, M. P. (1999) De- creased ATP synthesis is phenotypically expressed during increased en- ergy demand in fibroblasts containing mitochondrial tRNA mutations. Eur. J. Biochem. 259, 462– 469 32. Robey, R. W., Shukla, S., Finley, E. M., Oldham, R. K., Barnett, D., Ambud- kar, S. V., Fojo, T., and Bates, S. E. (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-medi- ated transport by the orally administered inhibitor, CBT-1((R)). Biochem. Pharmacol. 75, 1302–1312 33. Robey, R. W., Medina-Pérez, W. Y., Nishiyama, K., Lahusen, T., Miyake, K., Litman, T., Senderowicz, A. M., Ross, D. D., and Bates, S. E. (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 7, 145–152 34. Ambudkar, S. V. (1998) Drug-stimulatable ATPase activity in crude mem- branes of human MDR1-transfected mammalian cells. Methods Enzymol. Drug Combinations Evoke Collateral Sensitivity against ABCG2 NOVEMBER 7, 2014 • VOLUME 289 • NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 31409PDF Image | Curcumin with Either Gramicidin or Ouabain
PDF Search Title:
Curcumin with Either Gramicidin or OuabainOriginal File Name Searched:
PIIS0021925820333664.pdfDIY PDF Search: Google It | Yahoo | Bing
CO2 Organic Rankine Cycle Experimenter Platform The supercritical CO2 phase change system is both a heat pump and organic rankine cycle which can be used for those purposes and as a supercritical extractor for advanced subcritical and supercritical extraction technology. Uses include producing nanoparticles, precious metal CO2 extraction, lithium battery recycling, and other applications... More Info
Heat Pumps CO2 ORC Heat Pump System Platform More Info
CONTACT TEL: 608-238-6001 Email: greg@infinityturbine.com (Standard Web Page)